Literature DB >> 12538625

Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein.

Chao Wu Xiao1, Xiaojuan Yan, Yulian Li, Shrikanth A G Reddy, Benjamin K Tsang.   

Abstract

The purpose of the present studies was to examine the role and regulation of Fas-associated death domain-like IL-1- converting enzyme-like inhibitory protein [FLIP; long (FLIP(L)) and short (FLIP(S)) forms] in human ovarian epithelial cancer cells by TNFalpha and their significance in the resistance of the cells to the proapoptotic action of the cytokine. OV2008, A2780-s, and OVCAR-3 cells were cultured in serum-free media with or without cycloheximide (CHX, 10 micro g/ml) +/- TNFalpha (5, 10, 20 ng/ml) or transfected with a mammalian expression vector containing either a dominant negative inhibitor kappaB (IkappaB), FLIP(S) sense or antisense cDNA and cultured with or without TNFalpha. In the presence of CHX, TNFalpha increased caspase-8 and -3 cleavage and apoptosis. It also induced IkappaB phosphorylation, nuclear factor kappaB activation, and the expression of FLIP(S) but not of FLIP(L). Overexpression of dominant negative IkappaB attenuated TNFalpha-induced FLIP(S) expression and enhanced TNFalpha-induced apoptosis. Apoptosis induced by TNFalpha and CHX was facilitated by FLIP(S) antisense expression but attenuated by sense transfection. This study demonstrates that TNFalpha up-regulates FLIP(S) expression, and this effect is mediated by the activation of nuclear factor kappaB. The induction of FLIP(S) expression by TNFalpha might contribute to the resistance of ovarian epithelial cancer cells to the proapoptotic action of the cytokine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538625     DOI: 10.1210/en.2001-211024

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Anaphase-promoting complex/cyclosome controls HEC1 stability.

Authors:  L Li; Y Zhou; G-F Wang; S-C Liao; Y-B Ke; W Wu; X-H Li; R-L Zhang; Y-C Fu
Journal:  Cell Prolif       Date:  2011-02       Impact factor: 6.831

2.  Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.

Authors:  Bradley J Monk; Andrea Facciabene; William E Brady; Carol A Aghajanian; Paula M Fracasso; Joan L Walker; Heather A Lankes; Kristi L Manjarrez; Gwenn-Äel H Danet-Desnoyers; Katherine M Bell-McGuinn; Carolyn K McCourt; Alexander Malykhin; Robert M Hershberg; George Coukos
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 3.  Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.

Authors:  Kristin L White; David N Rider; Kimberly R Kalli; Keith L Knutson; Gail P Jarvik; Ellen L Goode
Journal:  Cancer Causes Control       Date:  2011-02-27       Impact factor: 2.506

4.  Multiple Functions of Cellular FLIP Are Essential for Replication of Hepatitis B Virus.

Authors:  Ah Ram Lee; Keo-Heun Lim; Eun-Sook Park; Doo Hyun Kim; Yong Kwang Park; Soree Park; Dong-Sik Kim; Gu-Choul Shin; Hong Seok Kang; Juhee Won; Heewoo Sim; Yea Na Ha; Byeongjune Jae; Seong Il Choi; Kyun-Hwan Kim
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

5.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue.

Authors:  Liang-Liang Yu; Hong-Gang Yu; Jie-Ping Yu; He-Sheng Luo; Xi-Ming Xu; Jun-Hua Li
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

Review 6.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

Review 7.  Tumor evasion from T cell surveillance.

Authors:  Katrin Töpfer; Stefanie Kempe; Nadja Müller; Marc Schmitz; Michael Bachmann; Marc Cartellieri; Gabriele Schackert; Achim Temme
Journal:  J Biomed Biotechnol       Date:  2011-11-15

Review 8.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

9.  Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.

Authors:  Kristin L White; Robert A Vierkant; Catherine M Phelan; Brooke L Fridley; Stephanie Anderson; Keith L Knutson; Joellen M Schildkraut; Julie M Cunningham; Linda E Kelemen; V Shane Pankratz; David N Rider; Mark Liebow; Lynn C Hartmann; Thomas A Sellers; Ellen L Goode
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

Review 10.  Chemoresistance in human ovarian cancer: the role of apoptotic regulators.

Authors:  Michael Fraser; Brendan Leung; Arezu Jahani-Asl; Xiaojuan Yan; Winston E Thompson; Benjamin K Tsang
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.